[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657451":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":28,"studyPopulation":20,"armGroups":29,"interventions":39,"overallOfficials":20,"centralContacts":45,"locations":55,"responsibleParty":106,"collaborators":20,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":117,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":20,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":133,"overallStatus":137,"whyStopped":20,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"IFN-I signature score","The interferon signature assessed by transcriptomic analysis and IFN-α concentrations measured using the Simoa assay will be compared across the different disease groups and with healthy volunteers.","Day 1 and Month 12 (if applicable)",[14,17],{"measure":15,"description":16,"timeFrame":12},"Clinical phenotype","Correlation between the extent of specific organ involvement and the activation of nucleic acid-sensing pathways, assessed by the levels of IFN-α production.",{"measure":18,"description":19,"timeFrame":12},"plasma IFN-α concentration","In vitro change in the IFN signature and IFN-α production in patients' PBMCs after exposure to selective inhibitors of overactivated IFN-I signaling pathways",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":24,"primaryPurpose":25,"observationalModel":20,"timePerspective":20,"maskingInfo":26},"NON_RANDOMIZED","PARALLEL","The aim of this study is to characterize the type I interferon (IFN-I) response, defined by both the IFN-I gene signature and plasma IFN-α levels, following stimulation with a panel of ligands specific for DNA- and RNA-sensing pathways in patients with systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies compared and in healthy volunteers.","BASIC_SCIENCE",{"masking":27,"maskingDescription":20,"whoMasked":20},"NONE","The investigators hypothesize that chronic overproduction of type I interferons (IFN-I) is driven by increased basal activation of nucleic acid-sensing pathways and\u002For heightened cellular responsiveness to endogenous nucleic acids, leading to sustained IFN-I signaling and persistent inflammation. The objective of the study is to characterize the IFN-I response by assessing both the interferon gene signature and plasma IFN-α levels following stimulation of PBMCs with a panel of DNA- and RNA-sensing pathway-specific ligands.\n\nThe SAFRAN study protocol comprises two study visits for patients: a mandatory Visit 1 (V1) and an optional Visit 2 (V2), the performance of which depends on the results obtained at V1. Healthy control participants will undergo Visit 1 (V1) only.\n\nDuring Visit 1 (V1), the investigator will perform a clinical assessment as part of routine disease management. Disease activity will be evaluated using validated clinical scoring systems. For patients with systemic lupus erythematosus (SLE), disease activity will be assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). For patients with systemic sclerosis, skin involvement will be evaluated using the modified Rodnan Skin Score (mRSS). In addition, disease activity will be assessed in all patients using the Physician Global Assessment (PGA) scale.\n\nDuring Visit 2 (V2), patients in whom an abnormality in interferon signaling is identified through the in vitro assays will undergo additional blood sampling during a routine follow-up visit conducted as part of standard clinical care. An additional blood volume of 12 mL will be collected to further characterize the abnormality detected in the previous sample (V1), within 12 months of the initial assessment.",[30,35],{"label":31,"type":6,"description":32,"interventionNames":33},"Patients","Patients with systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies",[34],"Biological: biological samples",{"label":36,"type":6,"description":37,"interventionNames":38},"control","Healthy volunteer",[34],[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":20},"BIOLOGICAL","biological samples","Healthy volunteers will undergo a blood draw of a total volume of 20 mL for the following analyses: ex vivo analysis of the interferon signaling pathway (12 mL) and biological sample collection, if the patient\u002Fholder of parental authority provides consent (8 mL).",[31,36],[46,51],{"name":47,"role":48,"phone":49,"phoneExt":20,"email":50},"Alexandre BELOT, MD, PhD","CONTACT","+3342786126","Alexandre.belot@chu-lyon.fr",{"name":52,"role":48,"phone":53,"phoneExt":20,"email":54},"Samira PLASSART","+33427855442","samira.plassart@chu-lyon.fr",[56,75,90],{"facility":57,"status":20,"city":58,"state":20,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Hôpital Femme-Mère-Enfant","Bron","69500","France","FR",{"type":63,"coordinates":64},"Point",[65,66],4.91303,45.73865,{"lat":66,"lon":65},[69,73],{"name":70,"role":48,"phone":71,"phoneExt":20,"email":72},"Alexandre BELOT, MD, Ph D","+33427856126","alexandre.belot@chu-lyon.fr",{"name":70,"role":74,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":76,"status":20,"city":77,"state":20,"zip":78,"country":60,"countryCode":61,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Hôpital Edouard Herriot","Lyon","69003",{"type":63,"coordinates":80},[81,82],4.84789,45.74906,{"lat":82,"lon":81},[85,89],{"name":86,"role":48,"phone":87,"phoneExt":20,"email":88},"Thomas BARBA, MD","+33472119583","thomas.barba@chu-lyon.fr",{"name":86,"role":74,"phone":20,"phoneExt":20,"email":20},{"facility":91,"status":20,"city":92,"state":20,"zip":93,"country":60,"countryCode":61,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Centre Hospitalier Lyon-Sud","Oullins","69495",{"type":63,"coordinates":95},[96,97],4.80755,45.71404,{"lat":97,"lon":96},[100,104],{"name":101,"role":48,"phone":102,"phoneExt":20,"email":103},"Maël RICHARD, MD","+33478843973","mael.richard@chu-lyon.fr",{"name":105,"role":74,"phone":20,"phoneExt":20,"email":20},"Mael RICHARD, MD",{"type":107,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100657451","investigation-of-type-i-interferon-excess-in-patients-with-systemic-autoimmune-diseases-and-genetic-type-i-interferonopathies-100657451",false,"NCT07837986","Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies","Type I Interferon Excess in Autoimmune Diseases and Genetic Type I Interferonopathies","SAFRAN","Inclusion Criteria:\n\nPatient\n\n* Patient followed at the Hospices Civils de Lyon (HCL) for their disease.\n* Patient aged over 6 years and under 60 years.\n* Body weight ≥ 25 kg.\n* Patient with a confirmed diagnosis of\n\n  * Systemic lupus erythematosus\n  * Myositis, histologically confirmed or not\n  * Systemic sclerosis,\n  * Mixed connective tissue disease, according to the Sharp or Kasukawa criteria Undifferentiated connective tissue disease, according to the criteria proposed by Mosca et al.\n  * Genetically confirmed monogenic lupus or monogenic interferonopathy.\n* Patient, parents, or legal guardians informed about the study and having signed the informed consent form.\n\nHealthy Volunteer Participants\n\n* Subjects aged over 6 years and under 60 years.\n* Body weight greater than or equal to 25 kg.\n* Participants, parents, or legal guardians who have been informed about the study and have provided written informed consent.\n\nExclusion Criteria:\n\nPatient\n\n* documented infection or symptoms consistent with a bacterial or viral infection within 2 weeks prior to sampling\n* Subjects currently participating in an interventional drug study\n* Vaccination within 1 month prior to sampling\n* Pregnant, parturient, or breastfeeding women\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals receiving psychiatric care\n* Individuals admitted to a healthcare or social care institution for reasons other than participation in the research\n* Adults subject to a legal protection measure\n* Individuals not affiliated with a social security scheme or not covered by an equivalent health insurance system\n\nHealthy Volunteer Participants\n\n* Documented infection or symptoms consistent with a bacterial or viral infection occurring within 2 weeks prior to sample collection.\n* Participant with a long-term chronic disease (ALD) or any chronic medical condition.\n* Participant with a primary immunodeficiency.\n* Vaccination within 1 month prior to sample collection.\n* History of neoplasia (\\\u003C 5 years) or ongoing neoplastic disease.\n* Pregnant, parturient, or breastfeeding women.\n* Individuals deprived of liberty by a judicial or administrative decision.\n* Individuals receiving psychiatric care.\n* Individuals admitted to a health or social care institution for purposes other than participation in research.\n* Adults subject to a legal protection measure (guardianship or curatorship).\n* Individuals not affiliated with a social security system or not benefiting from an equivalent health insurance scheme.",true,"ALL","6 Years","60 Years",{"count":121,"type":122},120,"ESTIMATED","INTERVENTIONAL",[125],"NA","Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies are characterized by chronic and excession IFN-I signaling and production contributing to disease pathogenesis. Aberrant IFN-I production can be triggered through the activation of multiple signaling pathways, particularly those involving intracellular and extracellular RNA and DNA sensing receptors.\n\nWe hypothesize that excessive IFN-I production results from an increased tonic activation state of nucleic acid sensors and\u002For an enhanced responsiveness of these sensors to endogenous nucleic acids, thereby sustaining pathological IFN-I signaling and chronic inflammation.\n\nThe aim of this study is to characterize the type I interferon (IFN-I) response, defined by both the IFN-I gene signature and plasma IFN-α levels, following stimulation with a panel of ligands specific for DNA- and RNA-sensing pathways.",[128,129,130,131,132],"Systememic Lupus Erythematosus","Systemic Sclerosis (SSc)","Inflammatory Myopathies","Connective Tissue Diseases","Type 1 Interferonopathies",[134,135,136],"Interferon","IFN signature","interferon-alpha","NOT_YET_RECRUITING","2026-09-18",{"date":140,"type":141},"2026-09-24","ACTUAL",{"date":143,"type":122},"2026-12-01",{"date":145,"type":122},"2033-01-01",{"name":5,"class":6},3]